Symbols / DRTS
DRTS Chart
About
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 630.53M |
| Enterprise Value | 571.82M | Income | -39.97M | Sales | — |
| Book/sh | 0.91 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 125 | IPO | — |
| P/E | — | Forward P/E | -15.39 | PEG | — |
| P/S | — | P/B | 8.13 | P/C | — |
| EV/EBITDA | -14.72 | EV/Sales | — | Quick Ratio | 7.90 |
| Current Ratio | 8.43 | Debt/Eq | 17.40 | LT Debt/Eq | — |
| EPS (ttm) | -0.52 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -25.56% |
| ROE | -54.38% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 85.26M |
| Shs Float | 57.35M | Short Float | 0.98% | Short Ratio | 1.39 |
| Short Interest | — | 52W High | 7.89 | 52W Low | 2.30 |
| Beta | 1.05 | Avg Volume | 331.19K | Volume | 814.08K |
| Target Price | $9.00 | Recom | Strong_buy | Prev Close | $7.31 |
| Price | $7.39 | Change | 1.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$8.43
Latest analyst target
3. DCF / Fair value
$9.00
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$8.43
Low
$5.00
High
$12.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-12-10 | main | Citigroup | Buy → Buy | $7 |
| 2025-11-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-29 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-15 | reit | Piper Sandler | Overweight → Overweight | $7 |
| 2024-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-08 | reit | Piper Sandler | Overweight → Overweight | $7 |
| 2023-12-15 | init | Citigroup | — → Buy | $8 |
| 2023-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-11-17 | main | Piper Sandler | Overweight → Overweight | $8 |
- Japan okays first-in-kind Alpha DaRT for hard-to-treat head and neck cancer - Stock Titan ue, 24 Feb 2026 14
- Cancer therapy Alpha DaRT advances in 5 U.S. trials with 2026 results ahead - Stock Titan hu, 29 Jan 2026 08
- New Strong Sell Stocks for January 20th - Yahoo Finance ue, 20 Jan 2026 08
- Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Exploring a 110% Potential Upside in Biotechnology - DirectorsTalk Interviews hu, 23 Oct 2025 07
- Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 - Seeking Alpha Fri, 23 Jan 2026 08
- New Strong Sell Stocks for January 20th - Zacks Investment Research ue, 20 Jan 2026 08
- Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks ue, 09 Dec 2025 08
- Wayne Mardle shares raw and emotional video about his 'brutal' grief - Daily Mail Sun, 22 Feb 2026 09
- DRTS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI Mon, 12 May 2025 05
- Alpha Tau Highlights Five Concurrent U.S. Trials With Multiple Milestones Ahead; Shares Slip - Nasdaq hu, 29 Jan 2026 08
- Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Promising 114% Potential Upside In Biotechnology - DirectorsTalk Interviews hu, 13 Nov 2025 08
- Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention - simplywall.st hu, 08 May 2025 07
- Can DRTS stock beat analyst upgrades - Quarterly Portfolio Review & Fast Exit/Entry Strategy Plans - mfd.ru hu, 05 Feb 2026 09
- Darts icon Wayne Mardle shares emotional video on ‘brutal’ grief after death of his wife - talkSPORT Sun, 22 Feb 2026 11
- New Strong Sell Stocks for January 27th - Yahoo Finance ue, 27 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 83.95K | 419.29K | -776.25K | -3.14M |
| TaxRateForCalcs | 0.23 | 0.23 | 0.23 | 0.23 |
| NormalizedEBITDA | -30.70M | -29.82M | -29.39M | -12.82M |
| TotalUnusualItems | 365.00K | 1.82M | -3.38M | -13.67M |
| TotalUnusualItemsExcludingGoodwill | 365.00K | 1.82M | -3.38M | -13.67M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -31.75M | -29.16M | -33.76M | -27.27M |
| ReconciledDepreciation | 1.10M | 1.07M | 979.00K | 776.00K |
| EBITDA | -30.34M | -27.99M | -32.76M | -26.49M |
| EBIT | -31.44M | -29.07M | -33.74M | -27.26M |
| NetInterestIncome | 3.93M | 4.72M | 1.77M | 195.00K |
| InterestExpense | 303.00K | 75.00K | 0.00 | 0.00 |
| InterestIncome | 4.28M | 4.83M | 1.79M | 211.00K |
| NormalizedIncome | -32.03M | -30.56M | -31.16M | -16.75M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -31.75M | -29.16M | -33.76M | -27.27M |
| TotalExpenses | 36.04M | 35.68M | 32.14M | 13.79M |
| TotalOperatingIncomeAsReported | -36.04M | -35.68M | -32.14M | -13.79M |
| DilutedAverageShares | 69.93M | 69.38M | 63.53M | 67.62M |
| BasicAverageShares | 69.93M | 69.38M | 63.53M | 67.62M |
| DilutedEPS | -0.45 | -0.42 | -0.53 | -0.40 |
| BasicEPS | -0.45 | -0.42 | -0.53 | -0.40 |
| DilutedNIAvailtoComStockholders | -31.75M | -29.16M | -33.76M | -27.27M |
| NetIncomeCommonStockholders | -31.75M | -29.16M | -33.76M | -27.27M |
| NetIncome | -31.75M | -29.16M | -33.76M | -27.27M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -31.75M | -29.16M | -33.76M | -27.27M |
| NetIncomeContinuousOperations | -31.75M | -29.16M | -33.76M | -27.27M |
| TaxProvision | 6.00K | 16.00K | 20.00K | 7.00K |
| PretaxIncome | -31.74M | -29.14M | -33.74M | -27.26M |
| OtherIncomeExpense | 365.00K | 1.82M | -3.38M | -13.67M |
| GainOnSaleOfSecurity | 365.00K | 1.82M | -3.38M | -13.67M |
| NetNonOperatingInterestIncomeExpense | 3.93M | 4.72M | 1.77M | 195.00K |
| TotalOtherFinanceCost | 41.00K | 39.00K | 21.00K | 16.00K |
| InterestExpenseNonOperating | 303.00K | 75.00K | 0.00 | 0.00 |
| InterestIncomeNonOperating | 4.28M | 4.83M | 1.79M | 211.00K |
| OperatingIncome | -36.04M | -35.68M | -32.14M | -13.79M |
| OperatingExpense | 36.04M | 35.68M | 32.14M | 13.79M |
| ResearchAndDevelopment | 27.02M | 26.42M | 20.89M | 11.45M |
| SellingGeneralAndAdministration | 9.02M | 9.26M | 11.25M | 2.34M |
| SellingAndMarketingExpense | 2.35M | 1.92M | 974.00K | 482.00K |
| GeneralAndAdministrativeExpense | 6.67M | 7.33M | 10.27M | 1.86M |
| OtherGandA | 6.67M | 7.33M | 10.27M | 1.86M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 70.38M | 69.67M | 69.11M | 66.97M |
| ShareIssued | 70.38M | 69.67M | 69.11M | 66.97M |
| TotalDebt | 12.54M | 13.28M | 5.19M | 0.00 |
| TangibleBookValue | 62.67M | 84.47M | 105.66M | -34.78M |
| InvestedCapital | 68.23M | 90.08M | 105.66M | -34.78M |
| WorkingCapital | 55.55M | 78.65M | 102.14M | 28.24M |
| NetTangibleAssets | 62.67M | 84.47M | 105.66M | -34.78M |
| CapitalLeaseObligations | 6.97M | 7.67M | 5.19M | 0.00 |
| CommonStockEquity | 62.67M | 84.47M | 105.66M | -34.78M |
| TotalCapitalization | 68.23M | 90.08M | 105.66M | -34.78M |
| TotalEquityGrossMinorityInterest | 62.67M | 84.47M | 105.66M | -34.78M |
| StockholdersEquity | 62.67M | 84.47M | 105.66M | -34.78M |
| RetainedEarnings | -147.51M | -115.76M | -86.60M | -52.84M |
| AdditionalPaidInCapital | 210.18M | 200.23M | 192.26M | 18.06M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 23.54M | 22.91M | 14.49M | 76.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 14.86M | 15.81M | 10.15M | 72.59M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 53.96M | ||
| DerivativeProductLiabilities | 3.34M | 3.60M | 5.63M | 18.62M |
| LongTermDebtAndCapitalLeaseObligation | 11.53M | 12.21M | 4.52M | 0.00 |
| LongTermCapitalLeaseObligation | 5.96M | 6.60M | 4.52M | 0.00 |
| LongTermDebt | 5.56M | 5.61M | ||
| CurrentLiabilities | 8.68M | 7.10M | 4.34M | 4.41M |
| CurrentDebtAndCapitalLeaseObligation | 1.01M | 1.06M | 669.00K | |
| CurrentCapitalLeaseObligation | 1.01M | 1.06M | 669.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.40M | 1.16M | 907.00K | 788.00K |
| PayablesAndAccruedExpenses | 6.26M | 4.88M | 2.76M | 3.62M |
| CurrentAccruedExpenses | 2.62M | 2.24M | 1.28M | 2.37M |
| Payables | 3.65M | 2.65M | 1.49M | 1.25M |
| OtherPayable | 63.00K | 48.00K | ||
| DuetoRelatedPartiesCurrent | 118.00K | 79.00K | 63.00K | 48.00K |
| AccountsPayable | 3.53M | 2.57M | 1.42M | 1.20M |
| TotalAssets | 86.20M | 107.39M | 120.15M | 42.22M |
| TotalNonCurrentAssets | 21.98M | 21.63M | 13.67M | 9.57M |
| NonCurrentPrepaidAssets | 432.00K | 471.00K | 391.00K | 2.03M |
| NetPPE | 21.54M | 21.16M | 13.28M | 7.55M |
| AccumulatedDepreciation | -4.05M | -2.96M | -1.89M | -912.00K |
| GrossPPE | 25.60M | 24.13M | 15.17M | 8.46M |
| ConstructionInProgress | 2.00M | 0.00 | ||
| OtherProperties | 17.49M | 18.07M | 14.58M | 7.96M |
| MachineryFurnitureEquipment | 859.00K | 813.00K | 593.00K | 501.00K |
| LandAndImprovements | 5.25M | 5.25M | 0.00 | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 64.23M | 85.76M | 106.48M | 32.64M |
| RestrictedCash | 3.25M | 3.15M | 850.00K | 618.00K |
| PrepaidAssets | 1.04M | 472.00K | 784.00K | 227.00K |
| Receivables | 332.00K | 344.00K | 313.00K | 480.00K |
| OtherReceivables | 332.00K | 344.00K | 313.00K | 480.00K |
| CashCashEquivalentsAndShortTermInvestments | 59.60M | 81.79M | 104.53M | 31.32M |
| OtherShortTermInvestments | 45.88M | 69.13M | 98.69M | 8.08M |
| CashAndCashEquivalents | 13.72M | 12.66M | 5.84M | 23.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -22.02M | -24.36M | -24.78M | -14.74M |
| IssuanceOfDebt | 0.00 | 5.25M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -2.24M | -6.40M | -904.00K | -2.93M |
| InterestPaidSupplementalData | 321.00K | 52.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 5.00K | 16.00K | 8.00K | 1.00K |
| EndCashPosition | 13.72M | 12.66M | 6.69M | 23.85M |
| BeginningCashPosition | 12.66M | 6.69M | 23.85M | 16.17M |
| EffectOfExchangeRateChanges | 57.00K | -50.00K | -258.00K | 108.00K |
| ChangesInCash | 1.01M | 6.02M | -16.91M | 7.57M |
| FinancingCashFlow | 25.00K | 5.30M | 96.91M | 111.00K |
| CashFlowFromContinuingFinancingActivities | 25.00K | 5.30M | 96.91M | 111.00K |
| NetOtherFinancingCharges | 93.54M | |||
| ProceedsFromStockOptionExercised | 25.00K | 49.00K | 3.36M | 111.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 0.00 | 5.25M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 5.25M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 5.25M | 0.00 | 0.00 |
| InvestingCashFlow | 20.77M | 18.68M | -89.94M | 19.27M |
| CashFlowFromContinuingInvestingActivities | 20.77M | 18.68M | -89.94M | 19.27M |
| NetOtherInvestingChanges | -103.00K | -3.15M | ||
| NetInvestmentPurchaseAndSale | 23.11M | 28.23M | -89.03M | 22.20M |
| SaleOfInvestment | 148.19M | 191.86M | 32.10M | 30.28M |
| PurchaseOfInvestment | -125.08M | -163.63M | -121.14M | -8.08M |
| NetPPEPurchaseAndSale | -2.24M | -6.40M | -904.00K | -2.93M |
| PurchaseOfPPE | -2.24M | -6.40M | -904.00K | -2.93M |
| OperatingCashFlow | -19.78M | -17.96M | -23.88M | -11.81M |
| CashFlowFromContinuingOperatingActivities | -19.78M | -17.96M | -23.88M | -11.81M |
| ChangeInWorkingCapital | 1.17M | 2.49M | -307.00K | 585.00K |
| ChangeInOtherCurrentLiabilities | -726.00K | -809.00K | -1.15M | 0.00 |
| ChangeInOtherCurrentAssets | 789.00K | 729.00K | 535.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 1.62M | 2.37M | -986.00K | 2.32M |
| ChangeInPayable | 1.62M | 2.37M | -986.00K | 2.32M |
| ChangeInAccountPayable | 965.00K | 1.14M | 220.00K | 239.00K |
| ChangeInPrepaidAssets | -519.00K | 201.00K | 1.30M | -1.73M |
| OtherNonCashItems | 40.00K | 1.74M | -1.32M | 29.00K |
| StockBasedCompensation | 9.92M | 7.93M | 6.75M | 812.00K |
| DepreciationAmortizationDepletion | 1.10M | 1.07M | 979.00K | 776.00K |
| DepreciationAndAmortization | 1.10M | 1.07M | 979.00K | 776.00K |
| Depreciation | 1.10M | 1.07M | 979.00K | 776.00K |
| OperatingGainsLosses | -259.00K | -2.03M | 3.79M | 13.26M |
| GainLossOnInvestmentSecurities | -259.00K | -2.03M | 3.79M | 13.26M |
| NetIncomeFromContinuingOperations | -31.75M | -29.16M | -33.76M | -27.27M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for DRTS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|